Does the Presence of Cytokeratin Positive Individual Tumor Cells (N(0(I+))) in Sentinel Lymph Nodes Affect Clinical Outcomes in Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation

前哨淋巴结中细胞角蛋白阳性单个肿瘤细胞(N(0(I+)))的存在是否会影响接受加速部分乳腺照射治疗的乳腺癌患者的临床结果?

阅读:1

Abstract

PURPOSE: To report a primary objective clinical outcome of ipsilateral breast cancer recurrence following accelerated partial breast irradiation (APBI) with N(0(i+)) (single tumor cells or clusters <2mm) in sentinel lymph nodes. The secondary objective was to observe any incidence of ipsilateral breast failure. PATIENTS AND METHODS: Between March 2004 and April 2016, a total of 747 patients were enrolled in one of two APBI (Accelerated Partial Breast Irradiation) breast protocols (Phase II NCT01185145 and Phase III NCT01185132). Nineteen patients with N(0(i+)) disease were treated between February 2005 and December 2015. Patient eligibility included a primary invasive or DCIS tumor size <3 cm, N0(i+) disease, and margin width of >2 mm. All enrolled patients presented in this report had sentinel lymph node examinations. Clinical outcomes of ipsilateral breast, axillary and combined regional (breast or axillary) recurrences were analyzed. RESULTS: Median follow-up for all patients was 5 years (1-8 years). No patient experienced either ipsilateral breast or axillary recurrence. CONCLUSION: There has been scarce information/reporting of the treatment of patients with cytokeratin positive individual tumor cells N(0(i+)) with APBI. The authors have presented data which suggest that the successful outcomes of these patients might warrant further study.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。